Search
Temsirolimus
go.drugbank.com/drugs/DB06287ApprovedInvestigationalIt was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Dostarlimab
go.drugbank.com/drugs/DB15627ApprovedInvestigational[L33320] PD-1 receptors are found on T-cells and, when activated, serve to inhibit immune responses - some cancers leverage this system by overexpressing PD-1 ligands, thereby effectively inhibiting the … In April 2021, dostarlimab was granted accelerated approval by the FDA - as GlaxoSmithKline's dostarlimab-gxly (Jemperli) - for the treatment of adult patients with recurrent or advanced mismatch repair
Amoxicillin
go.drugbank.com/drugs/DB01060ApprovedInvestigationalVet approved[A190648] Amoxicillin has similar activity to [penicillin] and [ampicillin], but leads to higher serum concentrations than ampicillin.
Etrasimod
go.drugbank.com/drugs/DB14766ApprovedInvestigational[A261831] Etrasimod was approved on October 13, 2023, by the FDA under the brand name VELSIPITY for the treatment of adults with moderately to severely active ulcerative colitis.
Almonertinib
go.drugbank.com/drugs/DB16640ApprovedInvestigational[A231864] Almonertinib was also approved by the EMA on February 20, 2026.[L56068]
Antihemophilic factor, human recombinant
go.drugbank.com/drugs/DB00025ApprovedInvestigationalHuman recombinant antihemophilic factor (AHF) or Factor VIII, 2332 residues, glycosylated, produced by CHO cells
Glutethimide
go.drugbank.com/drugs/DB01437ApprovedIllicitIts use has been largely superseded by other drugs.
Iodine povacrylex
go.drugbank.com/drugs/DB09537ApprovedProlonged skin exposure could cause skin defatting manifested by the following signs/symptoms; localized redness, itching, drying and cracking of skin.
Mifepristone
go.drugbank.com/drugs/DB00834ApprovedInvestigationalIts inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua.
Glatiramer
go.drugbank.com/drugs/DB05259ApprovedInvestigational[A248880] It was approved by the FDA in 1996, and a generic version became available in 2017. … Glatiramer acetate exhibits several immunomodulatory effects and reduces the relapse rate of relapsing-remitting multiple sclerosis (RRMS) by 30%.